NewsBenzingaTruist Securities将Alnylam Pharmaceuticals评级下调至持有,并将目标价下调至225美元 Truist Securities将Alnylam Pharmaceuticals评级下调至持有,并将目标价下调至225美元 Benzinga 2026.11.02 15:38 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target Ahead of Palo Alto Networks Earnings, Here's What Barchart Data Says Comes Next for PANW Stock